gutflix
GI learning, personalised

Summary

TREATMENT WITH ELEXACAFTOR-TEZACAFTOR-IVACAFTOR SIGNIFICANTLY IMPROVES GASTROINTESTINAL SYMPTOMS, INTESTINAL ULTRASOUND FINDINGS AND PANCREATIC STIFFNESS IN PEOPLE WITH CYSTIC FIBROSIS

Anna Fichera

UEG Week Copenhagen 2023 | Poster

Hepatobiliary

October 16, 2023

A prospective study of 141 people with cystic fibrosis found that elexacaftor-tezacaftor-ivacaftor treatment significantly reduced gastrointestinal symptoms and ultrasound abnormalities, while pancreatic stiffness increased to normal values after one year of treatment.

KEY POINTS

- At baseline, 33% of patients reported abdominal pain and 34% had pathological intestinal ultrasound signs; after six months of elexacaftor-tezacaftor-ivacaftor treatment, these decreased to 6% and 15% respectively, with further improvement at 12 months.
- Median pancreatic stiffness in people with cystic fibrosis at baseline was significantly lower than in healthy controls (4.774 kPa versus 6.178 kPa, $p<0.05$).
- After one year of elexacaftor-tezacaftor-ivacaftor treatment, pancreatic stiffness significantly increased from 4.774 kPa to 5.442 kPa ($p<0.05$), approaching normal values seen in controls.
- This ongoing prospective study enrolled 141 patients at baseline, with 84 re-assessed at six months and 34 at 12 months, using 2D-shear-wave elastography and intestinal ultrasound to track changes.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e562cb8c-743c-11ee-a7f5-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.